Related Experiment Video
Updated: Mar 26, 2026
Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
Published on: April 18, 2015
Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer
Barbara M Grüner1, Isabel Winkelmann2, Annette Feuchtinger2
12. Medizinische Klinik, Technische Universität München, Munich, Germany.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is likely the most aggressive and therapy-resistant of all cancers. The aim of this study was to investigate the emerging technology of matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) as a powerful tool to study drug delivery and spatial tissue distribution in PDAC. We utilized an established genetically engineered mouse model of spontaneous PDAC to examine the distribution of the small-molecule inhibitor erlotinib in healthy pancreas and PDAC. MALDI IMS was utilized on sections of single-dose or long-term-treated mice to measure drug tissue distribution. Histologic and statistical analyses were performed to correlate morphology, drug distribution, and survival. We found that erlotinib levels were significantly lower in PDAC compared with healthy tissue (P = 0.0078). Survival of long-term-treated mice did not correlate with overall levels of erlotinib or with overall histologic tumor grade but did correlate both with the percentage of atypical glands in the cancer (P = 0.021, rs = 0.59) and the level of erlotinib in those atypical glands (P = 0.019, rs = 0.60). The results of this pilot study present MALDI IMS as a reliable technology to study drug delivery and spatial distribution of compounds in a preclinical setting and support drug imaging-based translational approaches. Mol Cancer Ther; 15(5); 1145-52. ©2016 AACR.
Insights
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) effectively tracks erlotinib distribution in pancreatic cancer. Lower drug levels in pancreatic ductal adenocarcinoma (PDAC) correlated with survival, highlighting MALDI IMS for preclinical drug studies.
Area of Science:
- Oncology
- Pharmacology
- Analytical Chemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and treatment-resistant cancer.
- Understanding drug distribution is crucial for improving PDAC therapy.
- Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is an emerging technology for spatial analysis.
Purpose of the Study:
- To evaluate MALDI IMS for studying drug delivery and spatial tissue distribution of erlotinib in PDAC.
- To investigate the correlation between erlotinib levels, tumor morphology, and survival in a PDAC mouse model.
Main Methods:
- Utilized a genetically engineered mouse model of spontaneous PDAC.
- Administered erlotinib to mice and analyzed tissue distribution using MALDI IMS.
- Performed histologic and statistical analyses to correlate drug levels with tumor characteristics and survival.
Main Results:
- Erlotinib levels were significantly lower in PDAC tissue compared to healthy pancreatic tissue.
- Survival correlated with the percentage of atypical glands and erlotinib levels within these atypical glands, not overall drug levels or tumor grade.
- MALDI IMS demonstrated reliability in assessing drug distribution in a preclinical setting.
Conclusions:
- MALDI IMS is a valuable tool for studying drug delivery and spatial distribution in preclinical cancer models.
- Drug distribution within specific tumor regions, like atypical glands, may be more critical for therapeutic outcomes than overall drug levels.
- This study supports the use of drug imaging for translational cancer research.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018